Company Snapshot: XGEN  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Xenogen to Present at CIBC World Markets Healthcare Conference

    ALAMEDA, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN), maker of advanced imaging systems designed to accelerate drug
discovery and development, today announced that David W. Carter, chairman and
chief executive officer, and Pamela Reilly Contag, Ph.D., president, will
present at the CIBC World Markets 16th Annual Healthcare Conference to be held
November 7-9, 2005 at The Waldorf-Astoria in New York City.
    Xenogen's presentation will take place at 10:30 a.m. Eastern Time on
Wednesday, November 9, 2005.  There will be a live audio webcast of the
presentation, which will be accessible through a link posted on the investor
relations section of Xenogen's website at http://www.xenogen.com.  The webcast will
be available for replay on Xenogen's website for two weeks through November
23, 2005.

    About Xenogen Corporation
    Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies.  Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time.  The technology is designed provide higher quality in vivo data
earlier in the drug discovery and development process.  VivoVision(TM)
Solutions are designed to improve discovery and pre-clinical research in
multiple therapeutic areas.  VivoVision(TM) Biosciences represents more than
15 years of experience in the creation and characterization of animal models,
including genetic modifications, comprehensive phenotyping, compound profiling
and custom design and production of light producing cells, microorganisms and
animals.
    More information is available at http://www.xenogen.com.

    NOTE:  Xenogen(R), Living Image(R), VivoVision(TM) and IVIS(R) are
trademarks of Xenogen Corporation.


SOURCE Xenogen Corporation




Back to Topback to top

Related links:
  • http://www.xenogen.com
    CONTACT:
    William A. Albright, Chief Financial Officer
    of Xenogen Corporation, +1-510-291-6100